Systemic modulation of TLSs through strategies such as CXCL13 blockade, or conversely, CXCL13‐encoding mRNA or viral vectors, holds promise for either suppressing pathogenic TLSs or enhancing their formation in cancer immunotherapy settings [199]. Here, CXCL13 is linked to cancer.